Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles.

Jpn J Cancer Res · 1999 · PMC5925985 · PMID 10076575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

KRN/m showed highly significant antitumor activity in comparison with the control group (Fig. 2B).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.